search
Back to results

Tiagabine to Enhance Slow Wave Sleep in Patients With Sleep Apnea (TESSA)

Primary Purpose

Sleep Apnea, Obstructive

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Tiagabine
Placebo
Sponsored by
Brigham and Women's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sleep Apnea, Obstructive focused on measuring arousal threshold, phenotype, tiagabine, slow wave sleep

Eligibility Criteria

18 Years - 79 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosed OSA (moderate-to-severe; apnea hypopnea index >15 events/hr)

Exclusion Criteria:

  • History of seizures

Sites / Locations

  • Sleep Disorders Research Program Brigham and Women's Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Tiagabine

Placebo

Arm Description

Tiagabine PO 12 mg before sleep

Placebo PO before sleep

Outcomes

Primary Outcome Measures

Apnea Hypopnea Index (AHI)
Number of apneas + hypopneas per hour of sleep. Hypopnea criteria: reduction in 30% of baseline flow plus 3% desaturation or arousal.

Secondary Outcome Measures

Slow Wave Sleep (% Total Sleep Time)
Fraction of sleep spent in stage N3
Arousal Threshold (Esophageal Pressure Swing)
The arousal threshold was quantified as the mean of all the nadir negative esophageal pressure swings immediately preceding an arousal at the end of an obstructive apnea or hypopnea during both placebo and tiagabine nights.

Full Information

First Posted
March 9, 2015
Last Updated
July 14, 2017
Sponsor
Brigham and Women's Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02387710
Brief Title
Tiagabine to Enhance Slow Wave Sleep in Patients With Sleep Apnea
Acronym
TESSA
Official Title
Inducing Slow Wave Sleep to Treat Obstructive Sleep Apnea
Study Type
Interventional

2. Study Status

Record Verification Date
July 2017
Overall Recruitment Status
Completed
Study Start Date
March 2015 (undefined)
Primary Completion Date
June 2016 (Actual)
Study Completion Date
July 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Brigham and Women's Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. Interestingly, the severity of OSA is profoundly reduced in deep sleep (called "slow wave sleep"), potentially via an increase in the stimulus required to arouse from sleep. Here the investigators test the idea that the medication called "tiagabine" improves slow wave sleep and reduces OSA severity. The investigators will also test whether tiagabine raises the arousal threshold (more negative esophageal pressure), and whether detailed OSA "phenotyping" characteristics can predict the improvement in OSA severity with this intervention.
Detailed Description
The current study tests the primary hypothesis that tiagabine improves sleep apnea severity in patients with moderate-to-severe sleep apnea (apnea hypopnea index measured in supine non-REM sleep; hypopneas defined by 3% desaturation or arousal). The investigators test three secondary hypotheses that tiagabine: increases the proportion of total sleep time in slow wave sleep raises the non-REM arousal threshold (more negative esophageal pressure) via (1). is preferentially effective in patients whose OSA phenotype predicts that an increase in the arousal threshold is sufficient to resolve OSA versus those without such favorable physiology. Favorable physiology is defined here as having a low ventilatory drive at which stable breathing is theoretically feasible ("stable Vdrive" is <100% above eupneic ventilatory drive) due to any combination of a "high" upper airway muscle response, "good" passive anatomy (high Vpassive), and "low" steady-state loop gain (see Owens RL et al SLEEP 2014; Wellman A et al J Appl Physiol 2011, 2013; Eckert DJ et al 2013 AJRCCM).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep Apnea, Obstructive
Keywords
arousal threshold, phenotype, tiagabine, slow wave sleep

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
18 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Tiagabine
Arm Type
Active Comparator
Arm Description
Tiagabine PO 12 mg before sleep
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo PO before sleep
Intervention Type
Drug
Intervention Name(s)
Tiagabine
Other Intervention Name(s)
Gabitril
Intervention Description
GABA reuptake inhibitor
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo comparator
Primary Outcome Measure Information:
Title
Apnea Hypopnea Index (AHI)
Description
Number of apneas + hypopneas per hour of sleep. Hypopnea criteria: reduction in 30% of baseline flow plus 3% desaturation or arousal.
Time Frame
1 night
Secondary Outcome Measure Information:
Title
Slow Wave Sleep (% Total Sleep Time)
Description
Fraction of sleep spent in stage N3
Time Frame
1 night
Title
Arousal Threshold (Esophageal Pressure Swing)
Description
The arousal threshold was quantified as the mean of all the nadir negative esophageal pressure swings immediately preceding an arousal at the end of an obstructive apnea or hypopnea during both placebo and tiagabine nights.
Time Frame
1 night

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
79 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosed OSA (moderate-to-severe; apnea hypopnea index >15 events/hr) Exclusion Criteria: History of seizures
Facility Information:
Facility Name
Sleep Disorders Research Program Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
28364504
Citation
Taranto-Montemurro L, Sands SA, Edwards BA, Azarbarzin A, Marques M, de Melo C, Eckert DJ, White DP, Wellman A. Effects of Tiagabine on Slow Wave Sleep and Arousal Threshold in Patients With Obstructive Sleep Apnea. Sleep. 2017 Feb 1;40(2):zsw047. doi: 10.1093/sleep/zsw047.
Results Reference
derived

Learn more about this trial

Tiagabine to Enhance Slow Wave Sleep in Patients With Sleep Apnea

We'll reach out to this number within 24 hrs